Vividion Therapeutics, Inc.

The Scripps Research Institute

Benjamin Horning

David S Weinstein

Benjamin F Cravatt

Matthew Patricelli

Dean Stamos

Gabe Simon

Ekaterina Vinogradova

Shota Kikuchi

Betty Lam

Jason Green

Zachary Owyang

Kristen Baltgalvis

Todd Kinsella

Robert Malmstrom

Brian Nordin

Larry Burgess

Don Rogness

Kelsey Lamb

Disclosed are compounds of Formula (I): or pharmaceutically acceptable salts or solvates thereof, wherein R, R, X, Y, Z, and W are as defined herein. The compounds are, for example, inhibitors of WRN helicase and useful in treating a proliferative disease, such as cancer.

Pharmaceutical compositions comprising WRN helicase inhibitors

Disclosed herein are compositions and methods for modulating cereblon neosubstrates. A small molecule modulator of Formula (I*), or a pharmaceutically acceptable salt or solvate thereof can be used to modulate cereblon neosubstrates.

Cereblon modulators and uses thereof

Disclosed herein are in vivo engineered cereblon protein and methods of making the same. The in vivo engineered cereblon protein can include a site-specific non-naturally occurring modification at cysteine 287 as set forth in SEQ ID NO:1, or cysteine 286 as set forth in SEQ ID NO:2 or 3, the modification comprising a moiety resulting from an in vivo Michael addition reaction between an exogenous Michael acceptor and the cysteine 287 as set forth in SEQ ID NO:1, or cysteine 286 as set forth in SEQ ID NO:2 or 3.

In vivo engineered cereblon protein

Growing community of inventors

San Diego, CA, United States of America

Benjamin Horning